Neoplasms, Breast — Lapatinib and Bevacizumab for Metastatic Breast Cancer
Citation(s)
A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer